Treatment failure in leishmaniasis: drug-resistance or another (epi-) phenotype?
about
Multidrug resistance: an emerging crisisMultilocus microsatellite typing of Leishmania and clinical applications: a reviewA Luciferase-Expressing Leishmania braziliensis Line That Leads to Sustained Skin Lesions in BALB/c Mice and Allows Monitoring of Miltefosine Treatment OutcomeThe host-protective effect of arabinosylated lipoarabinomannan against Leishmania donovani infection is associated with restoration of IFN-γ responsivenessNaloxonazine, an Amastigote-Specific Compound, Affects Leishmania Parasites through Modulation of Host-Encoded FunctionsClinical and Parasitological Features of Patients with American Cutaneous Leishmaniasis that Did Not Respond to Treatment with Meglumine AntimoniateIn vitro selection of miltefosine resistance in promastigotes of Leishmania donovani from Nepal: genomic and metabolomic characterization.Multiplexed Spliced-Leader Sequencing: A high-throughput, selective method for RNA-seq in Trypanosomatids.The Immunology of a Healing Response in Cutaneous Leishmaniasis Treated with Localized Heat or Systemic Antimonial Therapy.Genomic and Molecular Characterization of Miltefosine Resistance in Leishmania infantum Strains with Either Natural or Acquired Resistance through Experimental Selection of Intracellular Amastigotes.Immunomodulation of host-protective immune response by regulating Foxp3 expression and Treg function in Leishmania-infected BALB/c mice: critical role of IRF1.Quantitative Kinetoplast DNA Assessment During Treatment of Mucosal Leishmaniasis as a Potential Biomarker of Outcome: A Pilot Study.Functional Validation of ABCA3 as a Miltefosine Transporter in Human Macrophages: IMPACT ON INTRACELLULAR SURVIVAL OF LEISHMANIA (VIANNIA) PANAMENSIS.Genomic Appraisal of the Multifactorial Basis for In Vitro Acquisition of Miltefosine Resistance in Leishmania donovaniInvolvement of nucleoside diphosphate kinase b and elongation factor 2 in Leishmania braziliensis antimony resistance phenotypeAlice in microbes' land: adaptations and counter-adaptations of vector-borne parasitic protozoa and their hosts.Evaluating drug resistance in visceral leishmaniasis: the challenges.Recovery of antigen-specific T cell responses from dogs infected with Leishmania (L.) infantum by use of vaccine associated TLR-agonist adjuvant.Decreased antimony uptake and overexpression of genes of thiol metabolism are associated with drug resistance in a canine isolate of Leishmania infantum.Leishmania-derived trimannose modulates inflammatory response to significantly reduce Leishmania (L.) major-induced lesions.The Binomial Parasite-Host Immunity in the Healing Process and in Reactivation of Human Tegumentary Leishmaniasis.
P2860
Q21284693-8A4512B4-78AB-40B4-A620-38DE73F5E66FQ22810163-A3842D35-DBFC-4AEF-8041-5E77C7731DDEQ27303693-391FBEE0-7011-4923-AAB7-32389C8B13F7Q27316485-0B0F4B29-78D9-46E1-83A1-E7E2F67063FEQ28468455-5EB81FD0-10ED-44AA-A087-6F0D569BE575Q28552530-53E15267-943E-4B28-89A6-1C547CC591A6Q30380900-D3813076-DFA5-4E62-A9C6-8A16C4F79210Q33808133-C82E8477-D18C-4922-ACFF-B8A60644E64CQ35814748-015C7033-2F42-48E0-B736-67CE61878C92Q36001763-01804F88-AE80-41F1-B9DD-33D8BFCE94D3Q36226474-92324351-BA3A-45A2-92AA-7DEA478C8347Q36455737-5F05A7D6-DE51-495F-8F30-274800EE5067Q36850042-7CFD24E2-0389-44F2-B6E9-AFEC042E6B6AQ37023262-DE3C7D51-C030-4361-9AF8-34156BDCA7CCQ37501785-1C0D7B7C-F9D8-41BC-BE79-33020B6CF907Q38892717-BA98148B-72EE-444B-80FD-BD2602DE81A9Q39014583-3FAD4C01-FFB7-4463-8B5B-CC173A449558Q40528471-95DA2D95-976C-47C5-ACFA-0664C1F6D472Q42548785-4D8F8580-FBC5-446C-B9F0-1E01F7CB9534Q50072845-065CD0EA-1ACC-4731-A73A-8990B2208F83Q55408705-C81FC7ED-6E11-48EA-A7F7-7A0B0C9BB981
P2860
Treatment failure in leishmaniasis: drug-resistance or another (epi-) phenotype?
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Treatment failure in leishmaniasis: drug-resistance or another (epi-) phenotype?
@en
type
label
Treatment failure in leishmaniasis: drug-resistance or another (epi-) phenotype?
@en
prefLabel
Treatment failure in leishmaniasis: drug-resistance or another (epi-) phenotype?
@en
P2860
P50
P1476
Treatment failure in leishmaniasis: drug-resistance or another (epi-) phenotype?
@en
P2093
Jean-Claude Dujardin
Syamal Roy
P2860
P304
P356
10.1586/14787210.2014.916614
P577
2014-05-06T00:00:00Z